Evotec welcomes the FDA's “Roadmap to Reducing Animal Testing in Preclinical Safety Studies” which is aligned with our 30+ year commitment to ethics and the principles of 3-Rs (Replacement, Reduction and Refinement).
As part of this commitment Evotec has invested strategically over many years in New Approach Methodologies (NAMs). This investment includes human-based in vitro systems like organoids, sophisticated in silico modeling, AI/ML and other innovative platforms. These approaches complement our extensive experience in animal-based safety testing and offers potential for more accurate predictions of safety in humans.
Evotec’s pioneering investment in NAMs together with long term experience in animal-based safety studies and successful support of regulatory submissions makes us the ideal partner for the validation and implementation of parallel safety assessment strategies within the new paradigm.
We are committed to work with Partners, Regulatory bodies and Stakeholders to embrace the concepts outlined in the FDA Road Map and continue to drive ethical, innovative, scientifically rigorous safety assessment strategies for delivery of safe effective medicines to the clinic.
For further information on Evotec’s established and evolving NAMs expertise, please read our recent blog article.
